Concord Biotech Limited reported a robust start to fiscal year 2027, with Q1 FY27 revenues rising 26% year-on-year to ₹257 crore, driven by strong demand in its active pharmaceutical ingredients (API) segment and significant export growth. The Ahmedabad-based biopharmaceutical company posted a profit after tax (PAT) of ₹58 crore, up 31% from ₹44.4 crore in the corresponding quarter of the previous year. This performance marks a recovery from the headwinds faced in FY26, including regulatory delays and shifting customer procurement patterns, signaling renewed momentum in both domestic and international markets.

The financial results were disclosed following an earnings call held on August 3, 2026, with the transcript submitted to stock exchanges on August 7, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Joint Managing Director and CEO Ankur Vaid highlighted that the growth was broad-based across key product categories, including immunosuppressants, anti-infectives, oncology, and antifungals, rather than being dependent on a single segment. The company remains debt-free, holding cash and cash equivalents of over ₹442 crore as of June 30, 2026.

Financial Performance Highlights

*Note: Previous year figures derived from stated growth percentages.

Revenue from the API segment surged 42% to ₹219 crore, offsetting a 23% decline in formulation revenue, which stood at ₹39 crore. Management attributed the formulation dip primarily to the absence of Middle East tender supplies recorded in the prior year, noting that underlying domestic business grew by double digits when adjusted for this one-off factor. Export revenues grew by 46% year-on-year, reflecting increased inquiries from regulated and semi-regulated markets in Europe, Japan, and Latin America.

Operational Updates and Pipeline

The company secured Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration for mycophenolate mofetil and Tofacitinib tablets during the quarter. These approvals, combined with successful inspections by ANVISA in Brazil and PPB in Kenya, expand Concord’s addressable market. The injectable facility at Limbasi commenced commercial operations, though capacity utilization remained low at approximately 5% as the company focuses on domestic sales and customer audits before scaling up exports.

What the Numbers Show

The divergence between API and formulation performance underscores Concord’s strategic pivot toward high-margin fermentation-based APIs. While formulation revenue contracted, the 42% growth in API sales drove overall top-line expansion and margin improvement. The gross margin increase of 100 basis points to 78.9% reflects strong pricing discipline and favorable product mix. With EBITDA margins expanding by 190 basis points to 32%, the company is leveraging its scale advantages in fermentation technology to capture wallet share from competitors, particularly in anti-infective and oncology segments where new products like Nystatin and Fusidic Acid are gaining traction.

Looking ahead, management expects to sustain growth rates better than historical averages, supported by a pipeline of 2-3 new product launches annually. The company aims to utilize its existing infrastructure to reach ₹3,000 crore in revenue within five to six years, with approximately ₹2,200 crore projected from APIs and ₹600-700 crore from formulations. Capital expenditure for the quarter was modest at ₹9.5 crore, preserving the company’s net cash position for potential organic or inorganic growth opportunities in fermentation adjacencies.

Concord Biotech Limited shareholders approved all six resolutions at its 41st Annual General Meeting (AGM) held on July 31, 2026, including a contentious special resolution to enhance lending limits to group companies. The approval enables the biotechnology firm to advance loans and provide guarantees to subsidiaries, associates, and joint ventures pursuant to Section 185 of the Companies Act, 2013. However, the resolution faced significant resistance from institutional investors, highlighting a divergence in governance sentiment between promoter-aligned and independent public stakeholders.

The meeting was conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), with Central Depository Services (India) Limited (CDSL) facilitating remote e-voting from July 28, 2026, to July 30, 2026. Ashish Shah of Ashish Shah & Associates served as the scrutinizer, submitting his consolidated report on July 31, 2026, in compliance with Section 108 of the Companies Act, 2013 and Rule 20(xi) of the Companies (Management and Administration) Rules, 2014. Paritosh Trivedi, Company Secretary and Compliance Officer, submitted the voting results to the National Stock Exchange of India Limited and BSE Limited on August 1, 2026, under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results Overview

A total of 83,770 shareholders were on record as of July 24, 2026. No shareholders attended in person or via proxy; participation was exclusively through VC/OAVM (38 shareholders: four promoters, 34 public) and remote e-voting. All resolutions passed, but the margin varied significantly based on investor category.

Divergent Sentiment on Loan Limits

The special resolution for enhanced loan limits revealed a stark split in shareholder opinion. Promoter and promoter group shareholders, holding 46,116,608 shares, abstained from voting due to their interest in the agenda. Consequently, the outcome depended entirely on public shareholders. Public non-institutional shareholders voted overwhelmingly in favor with 99.99% support. In contrast, public institutional shareholders opposed the measure, with 56.60% voting against and only 43.40% in favor. Despite this institutional resistance, the resolution passed with 35,391,774 votes in favor out of 43,353,536 valid votes polled.

Other resolutions enjoyed near-unanimous support. The adoption of standalone and consolidated financial statements for FY26 received 99.69% affirmative votes. The dividend declaration was approved with 99.98% support. The re-appointment of Mr. Ankur Vaid (DIN: 01857225), who retires by rotation, secured 99.70% support. Similarly, the appointment of Mrs. Ekta Gupta as an independent director passed with negligible opposition, reflecting broad consensus on board composition.

What the Numbers Show

The voting pattern underscores a growing disconnect between institutional investors and retail shareholders regarding corporate governance practices at Concord Biotech. While institutions expressed clear disapproval of the enhanced lending limits—likely citing risk management concerns—the overwhelming support from non-institutional public shareholders ensured the resolution's passage. This dynamic suggests that while institutional scrutiny is intensifying, promoter-aligned or retail investor sentiment continues to drive key strategic approvals, potentially insulating management decisions from broader market skepticism.